Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the past few years tumor necrosis factor (TNF), also known as cachectin, has been isolated, cloned and now human recombinant TNF is available. This cytokine has numerous actions, which can be divided into four groups: 1) antitumor function; 2) immunomodulating activity and function in the inflammatory response; 3) effects on metabolism; 4) other functions. TNF was first identified for its anticancer activity; it is able to induce hemorrhagic necrosis in subcutaneously implanted tumors, due to the induction of free radicals in tumor cells and to vascular damage. It can also activate T-lymphocytes to become lymphokine-activated killer cells (LAK cells) against tumors. TNF also plays an important role in the inflammatory response: it mediates many of the immunologic features of T-cell function and of infection, and is essential in septic shock. TNF is a cause of the hypertriglyceridemia and the cachexia that characterize chronic infections and neoplasms. In vitro this cytokine causes growth of vascular endothelial cells; this observation suggests that it could have an atherogenic role. In in vivo experiments severe hepatic ischemia-reperfusion injury results in TNF release with subsequent local and systemic injury that was significantly reduced by anti-TNF antiserum pretreatment. Thus, TNF could be a cause of ischemic tissue damage. In conclusion, while TNF is known to play many roles, the intercellular network of the cytokines is not yet sufficiently understood and so we are only just beginning to comprehend the full implication of this important molecule in both histology and pathology.
 ...
PMID:[Tumor necrosis factor: a cytokine with multiple actions]. 156 77

When tumor is resected from patients as part of the natural course of their treatment, an attempt will be made to establish a tissue culture line of the tumor. The gene coding for tumor necrosis factor will be introduced into these tumor cells and the integration and expression of this gene will be tested. Patients will become eligible for this study only if they develop metastatic cancer that has failed all standard effective treatment and have no other effective treatment options available to them. Tumor cells will be injected intradermally and subcutaneously into the thigh of these patients. The amount of tumor injected will be less than 1/50th the total tumor burden of the patient. In previous studies we have shown that these gene-modified tumor cells are more immunogenic than the native unaltered tumor. Attempts will then be made to grow immune lymphocytes either from the tumor site or from the draining lymph nodes of these patients in order to use these lymphocytes for adoptive immunotherapy as detailed in previous protocols. The direct effect of the immunization with these immunogenic tumor cells will also be measured by assessing the impact on established tumor at other sites. Fifty patients receiving tumor inoculation will be included in this study.
 ...
PMID:Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. 156 41

In this report, the clinical value of a new interferon (INF) assay and measuring serum tumor necrosis factor (TNF) titer in renal cell carcinoma (RCC) patients is described. In order to find out ineffective cases, we established a new in vitro IFN assay system which was modified from human tumor clonogenic assay (HTCA) using an underlayer including monocytes (5 x 10(4)/dish) and lymphocytes (5 x 10(5)/dish) as the feeder cells obtained from human peripheral venous blood. This assay can evaluate both direct and indirect (immune mediated) antitumor effects. Various kinds of cytokines (TNF alpha, IL-1 alpha, -1 beta) were measured simultaneously in the cultured supernatants in vitro as well as the serum value in vivo by sandwich immunoenzymometric assay to compare the relationship between antitumor effect and clinical course. In the basic study, cultured ACHN cell line was used as the target cells. The inhibition of colony growth was observed in a dose relative manner. Continuous IFN-alpha exposure of 50 and 500 IU/ml in the presence of feeder cells showed a significant reduction of colony growth in comparison with cultured plates containing the drug only. Among the cytokines in the supernatants after incubation for 24 hours with IFN-alpha (500 IU/ml) including feeder cells, only TNF alpha showed significant elevation. In the clinical study, 31 RCC patients were tried for sensitivity testing using modified HTCA system. The sufficient colony growth was observed in 19 cases (61%). In 25 cases serum cytokines were compared with preoperative and postoperative values; twenty cases received post-operative IFN-alpha administrations, and 5 cases did not. Seven of the 20 cases with IFN-alpha therapy had some evaluable lesions. 1) The rates of colony survivals were correlated with TNF alpha titers in the supernatants (r = -0.90, p less than 0.01). 2) The serum levels of TNF alpha rose in 15 of the 20 cases (75%) after IFN-alpha therapy. The elevated value was significantly higher than the value of pretreatment period (p less than 0.05, paired t-test). 3) There was a significant correlation between the TNF alpha titers in the supernatants (in vitro) and in the sera (in vivo) treated with IFN-alpha. 4) All of 3 cases with low serum TNF alpha titers during IFN therapy showed progressive disease. But in 4 cases with high serum TNF alpha titers metastatic lesions did not change in more than one year.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[A new interferon-alpha assay system including indirect antitumor effect. Basic and clinical study of renal cell carcinoma]. 156 36

Both bacterial and mammalian heat shock proteins (HSP) are recognized by some T cells, and hsp60 recognition has been implicated in rheumatoid arthritis. We have developed a model to study the induction of hsp60 in human monocytic cell lines. An anti-mycobacterial hsp65 mAb (ML30), cross-reacting with human hsp60 was used to screen 21 human tumor cell lines in Western blot analysis. All T cell and B cell lymphomas constitutively expressed hsp60 protein at moderate to high levels, while little or no hsp60 protein was detected in two monocytic leukemia lines. Moderate to high levels of hsp60 mRNA and protein could be induced in the THP-I monocytic leukemia cell line by heat shock, retinoic acid, interferon (IFN)-gamma or tumor necrosis factor (TNF)-alpha treatment, the highest levels obtained with a combination of IFN-gamma/TNF-alpha. This was also seen using two rabbit anti-hsp60 antisera directed against the N-terminal or C-terminal part of the human hsp60 protein. The determinants detected by the ML30 mAb or the two rabbit anti-hsp60 antisera were not cell surface expressed, as measured with immunofluorescence (FACS) analysis on control cultured or cytokine treated cell lines. This could be a useful model for studies related to the induction of hsp60 in human cells.
 ...
PMID:Induction of human hsp60 expression in monocytic cell lines. 156 88

We have analyzed mechanisms controlling infiltration of T lymphocytes into tumor tissues. A lymphocyte chemotactic factor-b (LMF-b) produced by tumor infiltrating CD4+ T lymphocytes was purified. LMB-b was specifically chemotactic for CD8+ T lymphocyte. Furthermore, LMF-b augmented lymphocyte adhesion to high endothelial venule (HEV) cells. The binding of CD8+ T cells to HEV cells was specifically augmented by LMF-b. The LMF-b primarily acted on T lymphocytes, whereas tumor necrosis factor as well as IFN-gamma acted on HEV cells or fibroblast cells. The binding of lymphocytes to fibroblast cell line was not augmented by LMF-b. The augmentation of lymphocyte adhesion to endothelial cells by LMF-b was mediated by the lymphocyte function associated antigen-1/intercellular adhesion molecule (LFA-1/ICAM) pathway, the CD2/LFA-3 pathway, and the very late antigen-4/culture supernatant-1 (VLA-4/CS-1) pathway.
 ...
PMID:Functional analysis of mononuclear cells infiltrating into tumors. VI. The effect of lymphocyte chemotactic factors on lymphocyte adhesion to endothelial cells. 156 94

Factors defining the previously established differences in susceptibility of endothelial cells to the tumor-necrotizing agents, tumor necrosis factor (TNF) and lipid A, were investigated. Venous and arterial endothelial cells isolated from bovine and human umbilical cords showed large differences in proliferation rate and susceptibility to TNF and lipid A as measured by [3H]thymidine incorporation. The faster proliferating cells appeared more strongly inhibited by the agents. Also, using different isolates of human venous endothelial cells a similar correlation between proliferation rate and degree of inhibition was found. Growth stimulation of human venous cells with endothelial cell growth factor, but not the growth factor combined with heparin, increased the inhibitory action of the agents. Influence of the serum source was investigated by culturing human and bovine cells in the presence of human or bovine serum. Lipid A, but not TNF, was more inhibitory to cells of both species when cultured in bovine serum as compared to human serum. Supernatant of cultured tumor cells and serum from tumor-bearing mice increased the inhibitory effects of the agents as well. Data show that the action of the tumor-necrotizing agents on endothelial cells is defined by various factors, such as origin of the cells and culture conditions. In general, factors promoting cell proliferation tended to increase the susceptibility of the cells to the agents. The reported high vulnerability of tumors, wound tissue and placenta to induction of hemorrhage by these agents may be partially due to an enhanced sensitivity of the fast proliferating endothelium in these tissues.
 ...
PMID:Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A. 156 68

In this report we describe an experimental model of cachexia that fulfills the criteria of an early effect with a small tumor mass not related to the growth rate of the tumor, and progressive wasting of muscle and fat without a detectable loss of appetite. C-26.IVX is a cell line derived from murine colon-26 adenocarcinoma which retains the transplantability of the original tumor and induces true cachexia in syngeneic hosts. Evidence is presented to support a role for interleukin (IL-6) as a cachectic factor in the development of cancer cachexia in this model system. Thus, increasing levels of IL-6 in C-26.IVX-bearing mice correlate with the development of cachexia. If the primary tumors were resected, mice gained weight and the levels of IL-6 in the serum were reduced significantly. Moreover, monoclonal antibody to murine IL-6 (but not anti-tumor necrosis factor antibody) was able to significantly suppress the development of key parameters of cachexia in tumor bearing mice.
 ...
PMID:Evidence for the involvement of interleukin 6 in experimental cancer cachexia. 156 7

Extracorporeal photopheresis (ExP) has been shown to be an efficacious and well-tolerated therapy in the treatment of cutaneous T-cell lymphoma (CTCL) and systemic sclerosis. However, the precise mechanisms of its action have not been defined. Because of a correlation between the development of fever in the early phase of treatment of CTCL and subsequent anti-tumor responses, we examined the production of the proinflammatory, pyrogenic cytokines tumor necrosis factor-alpha (TNF), IL-6, IL-1 alpha, and IL-1 beta before and after ExP. Monocytes were purified from peripheral blood specimens of normal volunteers (n = 4) or from peripheral blood specimens of CTCL (n = 6) or systemic sclerosis (n = 3) patients that were obtained immediately prior to ExP and also directly from the photopheresis unit after ExP, just prior to reinfusion into the patient. Monocytes were then cultured under various conditions for 16 h, after which the culture supernatants were collected and assayed for specific cytokine production. ExP induced a significant increase in the production of TNF (p less than 0.008) and IL-6 (p less than 0.05) as compared to non-ExP-treated cells, whereas no significant differences were observed in IL-1 alpha (p less than 0.5) and IL-1 beta (p less than 0.2) production following ExP. Exposure of monocyte cultures to IFN-gamma (100 U/mL) either before or after ExP further enhanced TNF production by 4 to 28 times. In contrast, incubation with IFN-alpha (100 U/mL) had no significant effect on TNF production. Addition of TNF (500 U/ml) to monocyte cultures obtained prior to ExP resulted in a slight but insignificant increase in TNF production in 2 of 10 cases. However, when monocytes obtained prior to ExP were incubated with 8-methoxypsoralen (8-MOP, 100 ng/ml), exposed to ultraviolet light A (UVA, 2J/cm2), washed, and then incubated with TNF, a significant increase (p less than 0.01) in TNF production was observed in 8 of 10 cases, suggesting that the combination of 8-MOP and UVA may sensitize cells to TNF. Based on studies of endotoxin (LPS)-stimulated production of TNF by monocytes, levels of endotoxin in culture reagents or photopheresis equipment could not account for the increased production of TNF following treatment by ExP. Increased TNF production as a result of ExP may have important implications for treating both CTCL and systemic sclerosis because, in the case of CTCL, it could mediate numerous anti-tumor effects, whereas, in the case of systemic sclerosis, it could suppress collagen synthesis and induce collagenase production.
 ...
PMID:Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. 156 19

Hyperthermia can strikingly enhance tumor necrosis factor-alpha (TNF-alpha) cytotoxicity in vitro and in vivo. Other forms of TNF may have tumor therapeutic applications and their interaction with hyperthermia should also be assessed. We have compared the effect of heat on the in vitro cytotoxic response of murine L929 and EMT-6 and human T24 tumor cells to three TNF forms; recombinant human TNF-alpha, TNF-beta (lymphotoxin), and TNF-SAM2. A neutral red assay was used to measure toxicity at 18-20 h after initiating the heat treatment. TNF treatment preceded heating by 0-4 h or followed it by 2 h. Heating was done at 39 or 40.5 degrees C for 24 h, 40.5 or 42 degrees C for 1 h, or 43 degrees C for 1-1.5 h. We found that both TNF-beta and TNF-SAM2 toxicities, like that of TNF-alpha, were markedly enhanced by hyperthermia. Neither EMT-6 nor T24 cells responded consistently to any of these TNFs at heat doses up to 1 h at 43 degrees C, but an increment of only 15 min more at 43 degrees C sensitized EMT-6 cells and 1.5 h at 43 degrees C resulted in extensive EMT-6 cell killing. The T24 cells remained resistant except for variable responses at the highest TNF and heat doses. If TNF treatment was begun immediately before or 2 h after beginning to heat the EMT-6 cells, sensitization was reduced or eliminated, respectively, for all three TNF forms relative to protocols in which TNF was added 1, 2, or 4 h before heating.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Comparative in vitro studies of the potentiation of tumor necrosis factor (TNF)-alpha, TNF-beta, and TNF-SAM2 cytotoxicity by hyperthermia. 157 35

Synergistic enhancement of anti-tumor effects through the combined use of natural human interferon-alpha (nHuIFN-alpha) and natural human tumor necrosis factor-alpha (nHuTNF-alpha) enabled us to decrease the effective dose of each cytokine and consequently to reduce side effects. One hundred and twenty patients with advanced or recurrent solid cancer were entered in the trial from April 1985 to January 1988, of whom 112 patients were evaluable. A mixture of nHuINF-alpha and nHuTNF-alpha was injected intravenously as the maintenance dose 1 x 10(6)U or more/day for over 8 weeks. There was no response in 40 patients injected with the maintenance dose of 1 x 10(6)U/day, but of 72 patients receiving more than 2 x 10(6)U/day (10 micrograms of nHuIFN-alpha and 3 micrograms of nHuTNF-alpha), 4 had complete responses, 10 had partial responses, and 4 had minor responses. The overall response rate was 12.5% (14/112) and the rate was 19.5% in 72 patients with more than 2 x 10(6)U/day. Positive responses were as follows: hepatoma 3/8), renal cell cancer (4/11), breast cancer (4/17), ovarian cancer (1/2), malignant thymoma (1/1) and liposarcoma (1/1). Serious adverse effects like hypotension, oliguria and severe hepatobiliary toxicity were never experienced. The effective and adequate dose of the mixed preparation was considered 2 to 4 x 10(6)U/day/body.
 ...
PMID:Early phase II study of interferon-alpha and tumor necrosis factor-alpha combination in patients with advanced cancer. 157 56


<< Previous 1 2 3 4 5 6 7 8 9 10